Viewing Study NCT06477432



Ignite Creation Date: 2024-07-17 @ 11:10 AM
Last Modification Date: 2024-10-26 @ 3:33 PM
Study NCT ID: NCT06477432
Status: COMPLETED
Last Update Posted: 2024-06-27
First Post: 2024-06-21

Brief Title: Evaluation of the Safety and Performance Characteristics of Mesofiller Mesotox for the Correction of Wrinkles and Rehydration of the Face
Sponsor: Mesoestetic Pharma Group SL
Organization: Mesoestetic Pharma Group SL

Study Overview

Official Title: An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler of Mesoestetic Mesofiller Mesotox for the Correction of Wrinkles and Rehydration of the Face Clinical Investigation to Assess Safety and Performance of Mesofiller Mesotox
Status: COMPLETED
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The investigation is a single-centre interventional prospective non-randomized open-label uncontrolled single-arm un-blinded investigation for the evaluation of the safety and performance of the product mesofiller mesotox in the treatment of wrinkles and imperfections The clinical investigation is interventional and prospective in agreement with the pre-market regulatory status of the product
Detailed Description: The product mesofiller mesotox is a dermal filler manufactured by mesoestetic Pharma Group sl It was intended to be used as a temporary dermal filler for dermatological treatment for aesthetic purposes The product provides a temporary filling of dermal tissue to correct small skin defects such as wrinkles or scars in the upper part of the face while also providing hydration to the face

mesofiller mesotox is a sterile injectable gel colourless transparent non-pyrogenic reabsorbable product made out of cross-linked hyaluronic acid of non-animal origin produced via bacterial fermentation

This clinical investigation was conducted as an uncontrolled - no comparator medical device or other product was used The safety and performance of the treatment were evaluated by comparison of the condition with the state of the treated area before initiation of the procedure conducted by the trained Principal Investigator

The investigated product mesofiller mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects for whom a touch-up was considered beneficial Both sessions were conducted within 14-day intervals

The evaluation process during the medical examination was facilitated by photographic evidence taken before and after therapy at predetermined time points for reference

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None